Results 171 to 180 of about 130,730 (348)
Study of Acid Catalyzed Reactions of Proton Pump Inhibitors at D.M.E.
, 2007 Hanuman P. Gupta +3 more
openalex +1 more source
Advanced Science, EarlyView.This study identifies ADP‐ribosylation factor‐like protein 3 (ARL3) as a novel chaperone that stabilizes estrogen receptor α (ERα) in breast cancer. ARL3 promotes tumor growth by recruiting USP10 to remove ubiquitin chains from ERα, preventing its degradation.
Han Li +14 more
wiley +1 more source
Review article: proton pump inhibitors and bacterial overgrowth [PDF]
, 2005 Craig Williams, Kenneth E.L. McColl
openalex +1 more source
Evolution of proton pump inhibitor prescribing from 2017 to 2021 at 14 secondary and tertiary hospitals in China：a multicentre cross-sectional study [PDF]
, 2023 Min Zeng +4 more
openalex +1 more source
The safety of proton pump inhibitors [PDF]
Alimentary Pharmacology & Therapeutics, 2001 openaire +2 more sources
Advanced Science, EarlyView.A modular nanoplatform capable of sequentially reprogramming tumor microenvironment via cascade actions and responsive therapeutic functions is reported for breast cancer therapy. Via a dual‐targeting mechanism and responsive PD‐L1 antibody release, this nanoplatform enables amplified sonodynamic‐chemodynamic therapy and elicits robust immune response ...
Yang Yu +5 more
wiley +1 more source
Advanced Science, EarlyView.Cysteine‐tagged silk‐elastin‐like proteins, a family of tri‐block chimeric proteins that consist of a photothermal agent binding motif, silk motif, and elastin motif is developed to form a responsive in situ hydrogel for late‐stage and metastatic triple‐negative breast cancer.
Xinchen Shen +11 more
wiley +1 more source
Use of proton pump inhibitors in scandinavian children and adolescents: An observational study [PDF]
, 2023 Emilie Raaum Closs +3 more
openalex +1 more source